2022 Fiscal Year Final Research Report
Development of cancer specific monoclonal antibody for antibody drug
| Project/Area Number |
21K20789
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
0901:Oncology and related fields
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2021-08-30 – 2023-03-31
|
| Keywords | モノクローナル抗体 / フローサイトメトリー / ウェスタンブロット / 免疫組織化学染色 / がん / TROP2 / 抗腫瘍 / CBIS法 |
|---|
| Outline of Final Research Achievements |
Trophoblast cell surface antigen 2 (TROP2) is reported to be overexpressed in several types of cancer. A novel anti-TROP2 monoclonal antibody (clone TrMab-6) was developed using a Cell-Based Immunization and Screening (CBIS) method. TrMab-6 was useful for investigations using flow cytometry, western blot, and immunohistochemistry. TrMab-6 possesses in vitro antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) activities or in vivo antitumor activities using mouse xenograft breast cancer models by intraperitoneally treatment. TrMab-6 is also expected to have antitumor activity against other cancer types. TrMab-6 could become one of the cancer treatment strategies, including its application to antibody-drug conjugate and chimeric antigen receptor-T therapy.
|
| Free Research Field |
腫瘍生物学
|
| Academic Significance and Societal Importance of the Research Achievements |
TROP2に対する抗体は世界的に開発が進んでおり、医薬品としても用いられている。がん治療の標的となる一方で、TROP2の分子制御メカニズムはほとんど明らかになっていない。開発したTrMab-6は様々な実験でTROP2を検出できるため、今後の研究の発展に貢献できる。また、TrMab-6は乳がんモデルに対して抗腫瘍効果も有しているが、TROP2は肺がん、脳腫瘍、前立腺がんなど様々ながん種で高発現しているため、抗体薬物複合体やキメラ抗原受容体療法などへの応用も含め、TrMab-6が今後のがん治療戦略の１つとなる可能性がある。
|
